Who are IcoSema's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Continue GLP/GIP, Treatment with tirzapatide, DWJ211, LY3537031, HCP1202, NNC0487-0111.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/icosema.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

IcoSema — Competitive Intelligence Brief

IcoSema (IcoSema) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1/GIP receptor agonist. Area: Endocrinology.

phase 3 GLP-1/GIP receptor agonist GLP-1R, GIPR Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

IcoSema (IcoSema) — Novo Nordisk A/S. IcoSema is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IcoSema TARGET	IcoSema	Novo Nordisk A/S	phase 3	GLP-1/GIP receptor agonist	GLP-1R, GIPR
Continue GLP/GIP	Continue GLP/GIP	The Cleveland Clinic	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
Treatment with tirzapatide	Treatment with tirzapatide	University Medical Centre Ljubljana	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
DWJ211	DWJ211	Daewoong Pharmaceutical Co. LTD.	phase 3	Dual GLP-1/GIP receptor agonist	GLP-1R, GIPR
LY3537031	LY3537031	Eli Lilly and Company	phase 3	GLP-1/GIP receptor dual agonist	GLP-1R, GIPR
HCP1202	HCP1202	Hanmi Pharmaceutical Company Limited	phase 3	GLP-1/GIP receptor agonist	GLP-1R, GIPR
NNC0487-0111	NNC0487-0111	Novo Nordisk A/S	phase 3	Dual GLP-1/GIP receptor agonist	GLP-1R, GIPR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1/GIP receptor agonist class)

Dong-A ST Co., Ltd. · 2 drugs in this class
Hanmi Pharmaceutical Company Limited · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
University Medical Centre Ljubljana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IcoSema — Competitive Intelligence Brief. https://druglandscape.com/ci/icosema. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab